This inventor holds 3 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Transcriptx, Inc.. Active years: 2022-2023.
Company Filing History:
Years Active: 2022-2023
Title: Mirko Hennig: Innovator in Genetic Treatments
Introduction
Mirko Hennig is a prominent inventor based in Sunnyvale, CA (US). He has made significant contributions to the field of genetic treatments, particularly in the area of primary ciliary dyskinesia. With a total of 3 patents to his name, Hennig is recognized for his innovative approaches to medical challenges.
Latest Patents
Hennig's latest patents focus on the treatment of primary ciliary dyskinesia using synthetic messenger RNA. The patents disclose polynucleotides encoding peptides, proteins, enzymes, and functional fragments that can be effectively delivered to organs, such as the lung. These polynucleotides can be expressed within the cells of the organ and are designed to treat diseases or conditions associated with cilia maintenance and function, particularly those involving impaired function of the axoneme, such as DNAI1 or DNAH5.
Career Highlights
Mirko Hennig is currently associated with Transcriptx, Inc., where he continues to advance his research and development efforts. His work has garnered attention for its potential to revolutionize treatments for genetic disorders.
Collaborations
Hennig collaborates with notable colleagues, including David J Lockhart and Brandon Alan Wustman. Their combined expertise contributes to the innovative environment at Transcriptx, Inc.
Conclusion
Mirko Hennig stands out as a key figure in the field of genetic treatments, with a focus on addressing complex medical conditions through innovative solutions. His contributions are paving the way for advancements in the treatment of primary ciliary dyskinesia and beyond.